IN THE UNITED STATES PATENT AND TRADEMARK, OF

In re Patent Application of

SCHREIBER

Serial No. 09/913,159

Filed: August 10, 200

Title: VIRAL VACCINE

Assistant Commissioner for Patents Washington, DC 20231

issioner for Patents

MAR 2 1 2002

Atty Dkt. 35-213

C# M#

Group Art Unit: Unknown

Examiner: Unknown

Date: March 21, 2002

#8

Sir:

RESPONSE/AMENDMENT/LETTER

This is a response/amendment/letter in the above-identified application and includes an attachment which is hereby incorporated by reference and the signature below serves as the signature to the attachment in the absence of any other signature thereon.

Fees are attached as calculated below:

Total effective claims after amendment 0 minus highest number previously paid for 20 (at least 20) = 0 x \$ 18.00		\$	0.00
Independent claims after amendment previously paid for 3 (at least 3) = 0 minus highest number 0 x \$84.00		\$	0.00
If proper multiple dependent claims now added for first time, add \$280.00 (ignore improper)		\$	0.00
Petition is hereby made to extend the current due date so as to cover the filing date of this paper and attachment(s) (\$110.00/1 month; \$400.00/2 months; \$920.00/3 months)		\$	0.00
Terminal disclaimer enclosed, add \$ 110.00		\$	0.00
☐ First/second submission after Final Rejection pursuant to 37 CFR 1.129(a) (\$740.00) ☐ Please enter the previously unentered , filed ☐ Submission attached		\$	0.00
	Subtotal	\$	0.00
If "small entity," then enter half (1/2) of subtotal and subtract Applicant claims "small entity" status. Statement filed herewith		-\$	0.00
Rule 56 Information Disclosure Statement Filing Fee (\$180.00)		\$	0.00
Assignment Recording Fee (\$40.00)		\$	0.00
Other: Copy of March 11, 2002 Submission and copy of March 11, 2002 post card receipt			0.00
Copy of 2/13/02 Notification of Defective Response TOTAL FEE EN	ICLOSED	\$	0.00

The Commissioner is hereby authorized to charge any <u>deficiency</u>, or credit any overpayment, in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Account No. 14-1140. A <u>duplicate</u> copy of this sheet is attached.

1100 North Glebe Road, 8th Floor Arlington, Virginia 22201-4714 Telephone: (703) 816-4000 Facsimile: (703) 816-4100

BJS:eaw

NIXON & VANDERHYE P.C.

By Atty: B. J. Sadoff, Reg. No. 36,663

Signature:



Convinsaioner for Patents, Box FC1 United States Patent and Fracemark Office Washington, O.C. 2023:

U.S. APPLICATION NUMBER NO. FIRST NAMED APPLICANT ATTY. DOCKET NO.

09/913,159 Schreiber do 35-213

INTERNATIONAL APPLICATION NO
PCT/EP99/09759

I.A. FILING DATE PRIORITY DATE

B. J. Sadoff 12/03/1999 02/12/1999

B. J. Sadoff Nixon & Vanderhye 1100 North Glebe Road, 8th floor Arlington, VA 22201-4714

CONFIRMATION NO. 3633
371 FORMALITIES LETTER
OC000000007460949

Date Mailed: 02/13/2002

NOTIFICATION OF DEFECTIVE RESPONSE

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as an Elected Office (37 CFR 1.495):

U.S. Basic National Fee

Priority Document

- Biochemical Sequence Diskette
- Biochemical Sequence Listing
- Copy of IPE Report
- · Copy of references cited in ISR
- Copy of the International Application
- Copy of the International Search Report
- · Oath or Declaration
- Preliminary Amendments
- Request for Immediate Examination

DOCKETED

CLT/MATTER #_	32-313	
MAIL DATE		
DUE DATE		LOOK
FINAL DEADLIN		
DOCKETED BY	all	15
DOONE LED DI.		

The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

Applicant is required to complete the response within a time limit of ONE MONTH from the date of this Notification or within the time remaining in the response set forth in the Notification of Missing Requirements, whichever is the longer. No extension of this time limit may be granted under 37 CFR 1.136, but the period for response set in the Notification of Missing Requirements may be extended under 37 CFR 1.136(a).

The following items MUST be furnished within the period set forth below:

- The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):
 - A copy of the "Sequence Listing" in computer readable form has been submitted. The content of the computer readable form, however, does not comply with the requirements of 37 CFR 1.822 and/or 1.832, as indicated on the attached marked-up copy of the "Raw Sequence Listing."

- The computer readable format has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).
- APPLICANT MUST PROVIDE:
 - An initial or substitute computer readable form (CRF) of the "Sequence Listing."
 - An initial or substitute paper copy or compact disc of the "Sequence Listing," as well as an amendment directing its entry into the specification.
- For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:
 - For Rules Interpretation, call (703) 308-4216
 - To Purchase Patentin Software, call (703) 306-2600
 - For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov
 - A copy of the "Sequence Listing" in computer readable form has been submitted. The content of the computer readable form, however, does not comply with the requirements of 37 CFR 1.822 and/or 1.832, as indicated on the attached marked-up copy of the "Raw Sequence Listing."
 - The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

A copy of this notice MUST be returned with the response.

VONDA M WALLACE

Telephone: (703) 305-3736


PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY, DOCKET NO
09/913,159	PCT/EP99/09759	35-213

FORM PCT/DO/EO/916 (371 Formalities Notice)



Serial No.: Applicant: Title:	09/4/3/57 Schruber Date: 3/11/02/ Unal Jacon Ref: 35:213
Δ	Amendment
	Pages Specification Claims MAR 1 1 2002
	Claims
	Sheets Drawings: Formal
	Informal Assertion Occupation
	Declaration (Pages)
	Assignment
	Priority Document
	Base Issue Fee Transmittal
	Fee (Check)
	alate and it is the transition of the same of
Other:	Duality of a designate Thinks
/	Il deducte and I have the
Staterin	not be sequence high the most of the offer



Commissioner for Patents, Box PCT United States Patent and Traditivers (Africa Washington, D.C., 2023)

U.S. APPLICATION NUMBER NO. FIRST NAMED APPLICANT ATTY. DOCKET NO.

09/913,159 Schreiber do 35-213

INTERNATIONAL APPLICATION NO.

PCT/EP99/09759

LA. FILING DATE PRIORITY DATE

12/03/1999 02/12/1999

B. J. Sadoff Nixon & Vanderhye 1100 North Glebe Road, 8th floor Arlington, VA 22201-4714

CONFIRMATION NO. 3633
371 FORMALITIES LETTER
**OC00000007313549*

Date Mailed: 01/18/2002

NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as an Elected Office (37 CFR 1.495):

- U.S. Basic National Fees
- Priority Document
- Biochemical Sequence Diskette
- Biochemical Sequence Listing
- Copy of IPE Report
- · Copy of references cited in ISR
- Copy of the International Application
- Copy of the International Search Report
- Oath or Declaration
- Preliminary Amendments
- Request for Immediate Examination

DCCKETED

OLT/MATTER# 35	. 213
MAIL DATE	
DUEDATE March	19,2002
FINAL DEADLINE CLA	18,2007
DOCKETED BY MS	M
500112125 21	

The following items MUST be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

- The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):
 - A copy of the "Sequence Listing" in computer readable form has been submitted. The content of the computer readable form, however, does not comply with the requirements of 37 CFR 1.822 and/or 1.832, as indicated on the attached marked-up copy of the "Raw Sequence Listing."
 - The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).
 - APPLICANT MUST PROVIDE:
 - An initial or substitute computer readable form (CRF) of the "Sequence Listing."

- An initial or structure paper copy or compact disc of the "ence Listing," as well as an amendment directing its entry into the specification.
- For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:
 - For Rules Interpretation, call (703) 308-4216
 - To Purchase Patentin Software, call (703) 306-2600
 - For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

ALL OF THE ITEMS SET FORTH ABOVE MUST BE SUBMITTED WITHIN TWO (2) MONTH FROM THE DATE OF THIS NOTICE OR BY 22 or 32 MONTHS (where 37 CFR 1.495 applies) FROM THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(a).

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

A copy of this notice MUST be returned with the response.

VONDA M WALLACE

Telephone: (703) 305-3736

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY, DOCKET NO.
09/913,159	PCT/EP99/09759	35-213